GlassScriptPhysician profile
Sarah Catherine Stephenson
NPI 1053980995
$4,935.28
in general payments reported to CMS, 2019-2025
26 companies · $2,025 in 2025
The $2,025 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3.88 · 2022: $236 · 2023: $1,011 · 2024: $1,659 · 2025: $2,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,690 · Travel and Lodging: $5.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,689.58 |
| Travel and Lodging | $5.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $877.62 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $848.79 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $635.37 | 2023-2025 | |
| Glaxosmithkline, LLC. | $367.92 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Axsome Therapeutics, INC. | $296.98 | 2023-2025 | Auvelity, Sunosi |
| Medical Device Business Services, INC. | $235.99 | 2022 | |
| Amgen INC. | $235.37 | 2023-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $211.87 | 2024-2025 | |
| Edwards Lifesciences Corporation | $209.41 | 2025 | Sapien 3 Ultra Resilia |
| Novo Nordisk INC | $193.51 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $185.22 | 2024-2025 | |
| Exact Sciences Corporation | $117.47 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $103.74 | 2024-2025 | Rexulti |
| Astellas Pharma US INC | $82.05 | 2024-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $69.44 | 2025 | Caplyta |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.43 | 2024-2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $39.37 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.22 | 2023-2025 | Xifaxan |
| Verona Pharma, INC. | $25.81 | 2025 | Ohtuvayre |
| Lundbeck LLC | $22.89 | 2025 | Rexulti |
| Dexcom, INC. | $19.67 | 2025 | Dexcom G6 Transmitter |
| Biogen, INC. | $17.21 | 2023 | Skyclarys |
| Xeris Pharmaceuticals, INC. | $15.83 | 2024 | Gvoke Hypopen |
| Dynavax Technologies Corporation | $14.85 | 2025 | Heplisav-B |
| Idorsia Pharmaceuticals US INC | $14.37 | 2023 | Quviviq |
| Genentech USA, INC. | $3.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Stephenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.